Zynerba Press Releases

8 May 19 Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

6 May 19 Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)

2 Apr 19 Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

11 Mar 19 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights

7 Mar 19 Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

26 Feb 19 Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol

20 Feb 19 Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors

5 Feb 19 Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference

17 Dec 18 Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications

12 Dec 18 Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002